Pexidartinib Approval Status
FDA Approved: No
Generic name: pexidartinib
Company: Daiichi Sankyo
Treatment for: Tenosynovial Giant Cell Tumor
Pexidartinib is a CSF1R (colony stimulating factor-1 receptor) inhibitor in development for the treatment of symptomatic tenosynovial giant cell tumor (TGCT).
Development Status and FDA Approval Process for pexidartinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.